ArticleCancer research communications2026
Tumor Mutational Burden and Clinical Outcomes in Patients with Muscle-Invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The impact ofBJUI compass · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Pathologic complete response (pCR) after cisplatin-based neoadjuvant chemotherapy (NAC) is associated with improved outcomes in muscle-invasive bladder cancer (MIBC), but genomic predictors of benefit remain unvalidated. Based on observations in lung cancer, we hypothesized that patients with MIBC with high tumor mutational burden (TMB) would be unlikely to benefit from NAC, indicated by residual disease after cystectomy. Pretreatment tumor specimens from patients treated with cisplatin-based NAC were analyzed using Tempus xT/xR platforms. Sample size was prespecified by statistical design. High TMB was defined as the upper TMB quintile within the cohort. Correlation of TMB values and genomic variants with outcomes was performed using logistic regression, Cox proportional hazards models, and Kaplan-Meier techniques. Ninety-one patients were included, with a median follow-up of 63.6 months. pCR occurred in 31.9%. Median TMB was 8.9 mutations per megabase (Mut/Mb). Contrary to the prespecified hypothesis, higher TMB was associated with more favorable outcomes. Patients in the upper TMB quintile had a numerically higher pCR rate (47.4% vs. 27.8%; P = 0.165) and improved relapse-free survival (RFS)/overall survival [OS; hazard ratio (HR), 0.456; P = 0.08 and HR, 0.495; P = 0.16]. Using a clinically relevant cutoff, TMB ≥ 10 Mut/Mb was associated with higher pCR [43.6% vs. 23.1%; odds ratio (OR), 0.39; P = 0.044] and improved RFS (HR, 0.330; P < 0.001) and OS (HR, 0.388; P = 0.013). Exploratory analyses showed a trend toward enrichment of mismatch repair alterations (OR, 3.57; P = 0.087) in TMB-high tumors. Baseline TMB ≥ 10 Mut/Mb was associated with improved pathologic response and survival in MIBC treated with cisplatin-based NAC and warrants prospective evaluation in contemporary perioperative regimens. SIGNIFICANCE: In MIBC treated with cisplatin-based neoadjuvant chemotherapy, we found that baseline TMB ≥10 Mut/Mb was associated with higher pCR rates and improved RFS and OS. These findings support the prospective study of TMB as a prognostic biomarker in contemporary perioperative treatment regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.